Employment Application Form

Employment Application Form

Applicant Information

 

Education

 

References

 

Previous Employment

 

Military Service

  • I certify that my answers are true and complete to the best of my knowledge. If this application leads to employment, I understand that false or misleading information in my application or interview may result in my release.
 

Verification

LOOKING TO THE FUTURE

colcigel-logo

A single dose topical colchinium for acute gout flares.

OUR SCIENCE

Gensco® Pharma’s abilities provide boundless possibilities for improving health utilizing our unique preparations, innovative dosing methods, and proprietary drug delivery technologies.

Transdermal Technology Gensco® Pharma has developed and patented a unique transdermal drug delivery system... read more

MDose® Gensco® Pharma’s patented topical metered dose applicator dispenses an exact and consistent dose of medication with every pump... read more

PRODUCTS

LidoDose® The Single Dose™ Topical Anesthetic & Antiseptic for Preprocedural Use... read more

ColciGel® Prepare for the flare with the first transdermal treatment for gout flares... read more

Astero® The first FDA-approved prescription combination drug-device hydrogel containing Lidocaine 4% HCl for associated pain, wound healing and vasculitis.... read more

LiDORx® Delivers fast controlled pain relief at the site... read more

SpeedGel Rx® Non-NSAID alternative for pain, inflammation and bruising. Targeting the source of pain... faster... read more

PROFESSIONAL EVENTS

There are no upcoming events at this time.   Go to full list of events here.

GENSCO® TRENDING

Gensco® Pharma Announces RizaFilm® Commercialization Update in the United States September 26, 2023 Featured, Industry, Press Release, Product Update - Gensco® Pharma, a specialty pharmaceutical company, in partnership with IntelGenx is announcing the anticipated launch of RizaFilm® for Q1-2024. RizaFilm®… more...

Looking To The Future

 

 

A single dose topical colchinium for acute gout flares.

See all news